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Introduction
The silent killer, hypertension (HTN), impacts about 1 in 3 U.S. adults, contributing to
roughly 1,000 deaths per day in the U.S., and increases healthcare costs for HTN patients by
three times compared to costs for patients without HTN.1,2 High blood pressure (BP) in the early
1900s was thought to be a consequence of age and not a risk factor that needed controlling.
Now, it is well known that high BP is associated with greater incidence of mortality.3 It increases
a person’s risk for a number of life‐threatening conditions, such as ischemic heart disease,
stroke, heart failure, atherosclerosis, and renal insufficiency. Furthermore, only about 54% of
U.S. patients with HTN have their BPs under control.4 As such, health authorities and clinicians
continue to research a means by which patients can achieve better control of this disease.
Improved control of this disease is evidenced by reductions in BP values, usually seen after
lifestyle modifications and/or pharmacological therapies. Over the years, the Joint National
Committee (JNC) has redefined control, but in its most recent guidelines, JNC 7 classified BP
into four classes 5:
BP Classification
Systolic BP (mmHg)
Diastolic BP (mmHg)
Normal
<120
and <80
Prehypertension
120‐139
or 80‐89
Stage 1 HTN
140‐159
or 90‐99
Stage 2 HTN
≥160
or ≥100
Adapted from JNC 7 Express: The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: U.S.
Dept. of Health and Human Services; 2003.
In addition, JNC categorized BP goals based on patient age and comorbidities. For
patients aged 60 and older, who do not have co‐existing diabetes or chronic kidney disease
(CKD), the BP goal is <150/90 mmHg.6 As for patients aged 18‐59 without co‐existing major
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comorbidities, and for patients aged 60 and older with diabetes and/or CKD, the BP goal is
<140/90 mmHg.
In order to achieve these BP goals, the guidelines recommend four different drug classes
as first‐line treatment for HTN: angiotensin‐converting enzyme (ACE) inhibitors, angiotensin
receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide‐type diuretics.6 In many
cases, patients will require a minimum of two antihypertensive drugs for BP control.5
Currently, 1 in 5 U.S. adults are not aware that they have HTN; thus, a minimum of 20%
of patients have BPs that are not at goal.7 With such a large number of patients untreated and
uncontrolled, efforts have been made to improve patient attainment of these BP goals. Single‐
pill fixed‐dose combination drugs were made available for this purpose. This option reduces
medical costs for patients, increases medication compliance, and provides greater therapeutic
results. Looking at trends for fixed‐dose combination antihypertensive therapy, a commonly
used formulation is a thiazide diuretic combined with an ARB.8
Per the European Society of Hypertension‐European Society of Cardiology guidelines,
agents used in combination therapy are more effective when they have complementary
mechanisms of action, such as those that occur between a thiazide and an ARB.9 While a
thiazide works in the kidney to inhibit sodium reabsorption and increase sodium and water
excretion, an ARB blocks angiotensin II receptor effects on cells. ARBs block the
vasoconstriction and aldosterone‐secretion effects of angiotensin II, consequently inhibiting
reabsorption of sodium and water at the distal tubules of the kidneys.10,11 These two drug
classes work in conjunction to ultimately lower BP. While the current guidelines suggest that
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most patients with uncontrolled BP will require two antihypertensive drugs, the next questions
to answer are how much of each drug is needed and what numerical drop in BP is required for
an effective combination. The dose‐dependent side effects of these drugs should also be
considered. In particular, some providers find no benefit in treating patients with the lowest
dose of hydrochlorothiazide (HCTZ), a common antihypertensive thiazide currently used in
practice, and instead start treatment with a moderate dose of HCTZ. On the contrary, some
providers find there is no difference in BP lowering effects when comparing low versus
moderate HCTZ dosing. This anecdotal information poses the question of whether BP is
lowered more effectively with 25 mg of HCTZ compared to 12.5 mg of HCTZ, when used in dual
therapy with an ARB, over a minimum course of 8 weeks.
Discussion
A comprehensive literature review was done to evaluate the BP lowering effects of low
versus high dose HCTZ in combination therapy, specifically, when HCTZ is combined with an
ARB. Several clinical trials and pooled analyses were found that addressed this comparison.
In a phase III, randomized, double‐blinded trial by Rump et al.9, the efficacy and
tolerability of HCTZ 12.5 mg versus 25 mg in dual antihypertensive therapy was examined. This
16‐week study had two phases during which all BP measurements were made using a
standardized sphygmomanometer and taken at the trough of the medication therapeutic
window. All patients were allowed to rest for at least 10 minutes prior to having their BP
measurements taken. During phase I of the trial, week 0 to week 8, patients who failed to
achieve adequate BP control on olmesartan (OM) monotherapy were entered into phase II of
the trial and randomized into 1 of 4 groups: OM 40 mg, OM/HCTZ 20/12.5 mg, OM/HCTZ
3

40/12.5 mg, and OM/HCTZ 40/25 mg. After an additional 8 weeks of dual therapy, results
revealed that the addition of HCTZ showed statistically significantly larger BP reductions versus
monotherapy OM and that these reductions were dose‐dependent. Systolic blood pressure
(SBP) and diastolic blood pressure (DBP) reductions were greater in the OM/HCTZ 40/25 mg
versus 40/12.5 mg group. The OM/HCTZ 40/25 mmHg group showed the greatest number of
patients achieving target BPs, followed by the OM/HCTZ 40/12.5 mmHg group. In both groups,
the onset of efficacy was seen after 4 weeks of dual therapy, with a majority of the SBP and
DBP reductions seen by 8 weeks of dual therapy. When evaluating safety and tolerability, the
occurrence of treatment‐emergent adverse events was comparable across all treatment
groups. Specifically, however, metabolic and nutritional related adverse events were more
commonly reported in the OM/HCTZ 40/25 mg group versus the 40/12.5 mg group. More
importantly, in this large randomized study, patients with stage 2 HTN had the greatest SBP and
DBP reductions with the OM/HCTZ 40/25 mg combination group. However, these BP reductions
were only a few mmHg greater than those achieved by the group taking OM/HCTZ 40/12.5 mg.
In addition, the sample size in the OM/HCTZ 40/25 mg group was nearly half the size of the
OM/HCTZ 40/12.5 mg group, which potentially underestimates the overall rate of adverse
events related to the higher dose group. Overall, this study suggested that the 25 mg HCTZ
group had greater efficacy in BP reduction compared to the 12.5 mg HCTZ group when used in
combination with an ARB. Nevertheless, its results were limited by the much smaller sample
size of the higher dose HCTZ group compared to the lower dose HCTZ group.
Shortly after the Rump et al.9 trial results were published, Rosenbaum et al.12 conducted
a pooled analysis that included two phase III, randomized, double‐blinded trials, one of which
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was Rump’s study. In the pooled analysis, data were taken from two similarly designed studies
evaluating OM/HCTZ combination therapy at various doses versus OM monotherapy. Evidence
from this analysis revealed that although all patients on combination therapy achieved greater
BP reductions compared to OM monotherapy, the OM/HCTZ 20/25 mg and 40/25 mg groups
achieved the greatest reductions in both SBP and DBP. Both of these reductions which were
statistically significant. As for medication tolerability and safety, a lower incidence of treatment‐
emergent adverse events, all of which were considered drug unrelated, were associated with a
lower dose of HCTZ. The authors of this pooled analysis concluded that doubling the dose of
HCTZ in combination therapy allowed for greater antihypertensive effects, thus supporting the
use of HCTZ 25 mg over 12.5 mg. The authors’ conclusions are further strengthened as they are
consistent with the current JNC treatment guidelines, which recommend add‐on therapy
(addition of a second drug) instead of increasing a monotherapy dose.
In 2016, a separate investigation by Rump et al.13 (a phase III randomized, parallel‐group
trial), revealed data that supported the addition of HCTZ to dual therapy OM and amlodipine. In
this study, patients were on dual antihypertensive therapy for 8 weeks, during which those
patients with inadequate BP control by week 8 were then randomized into 1 of 3 groups.
Patients were either continued on the same dual therapy or had HCTZ 12.5 mg or 25 mg added
to their regimen. Similarly, as performed in the trials discussed above, an average of 3 BP
measurements were recorded in this study. Compared to the dual therapy OM and amlodipine
group, the triple therapy group with HCTZ 25 mg was the only group that achieved statistically
significant BP reductions. However, both low and high dose HCTZ groups achieved target BP
goals and greatest seated BP reductions by week 16. Between the HCTZ groups, the reductions
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in systolic and diastolic BPs were comparable. When BPs were measured by ambulatory‐
monitoring, a greater percentage of patients in the low dose HCTZ group reached their
ambulatory BP goal compared to the high dose HCTZ group, despite both groups having similar
reductions in BP. Unlike the prior studies, the Rump et al.13 2016 study reported that the
number of treatment‐emergent adverse events were comparable among all groups, including
between both triple therapy groups. Regardless, these study results favor the use of higher
dose HCTZ in combination antihypertensive therapy. This study’s strengths are its large sample
size and randomization design, which more accurately reflect real‐life practices. Its weakness,
however, is its relatively short duration, which does not provide long term data on the
antihypertensive effects of these medications.
In contrast to the above studies, a large, open‐label, non‐interventional, observation
study by Bramlage et al.14 revealed no statistically significant differences in BP reduction
between OM/HCTZ 40/12.5 mg and 40/25 mg doses. Both treatment groups had statistically
significant BP reductions compared to baseline. Similar to findings observed in the Rump et al.9
2010 study, a greater percentage of patients in the HCTZ 12.5 mg group achieved target BP by
the end of the study observation period. However, the limitations of this observational study
are that it lacks a control group, randomization, and information on medication compliance.
Nevertheless, the study design reflects real‐life situations, such as variations in daily medication
dose times and in medication compliance. Moreover, the data revealed no significant
differences in efficacy between low and high dose HCTZ antihypertensive combination therapy.
Lastly, a retrospective study by Neldam et al.15 found that in patients with both HTN and
moderate to severe renal impairment, some patients observed better BP outcomes with low
6

dose HCTZ combination therapy. This particular study reviewed pooled data from seven
independent randomized and double‐blinded trials, comparing effects of monotherapy
telmisartan with placebo versus combination therapy telmisartan with HCTZ 12.5 mg or 25 mg.
Specifically, all baseline SBP groups, except those groups with SBPs from 140 to 159 mmHg or
≥170 mmHg, receiving the T80/H25 treatment showed smaller SBP reductions from baseline
compared to those in the T80/H12.5 group. Similarly, patients in the T80/H25 group with
baseline DBPs ≥105 mmHg, had smaller BP reductions when compared to the T80/H12.5
treatment group. Overall, the study results suggest that in some cases, low dose HCTZ has
better efficacy compared to high dose HCTZ in dual antihypertensive therapy. The reasons for
these findings are not apparent, however, they may have resulted from either the small
T80/H12.5 group sample size or the post hoc analysis study design.
In summary, most of the evidence in the above studies suggests that HCTZ 25 mg used
in combination therapy with an ARB has greater BP lowering effects than HCTZ 12.5 mg in
combination with the same dose of the ARB. Nonetheless, patients in the HCTZ 12.5 mg group
still exhibited great reductions in BP when compared to monotherapy (ARB alone) or placebo
groups. In many instances, the differences in BP reduction between the groups receiving 12.5
mg and 25 mg only varied by a few mmHg. Though most of the studies showed superiority of
combinations with 25 mg versus 12.5 mg of HCTZ, some of the studies showed a greater
percentage of patients achieved target BP goals on 12.5 mg versus 25 mg of HCTZ. However,
the reason for this discrepancy was not explained. Lastly, a majority of the studies found that
both HCTZ doses were well tolerated, with comparable treatment‐emergent adverse events.
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Conclusion
The evidence in the currently available literature suggests that the combination of an
ARB with HCTZ at a 25 mg dose compared to a 12.5 mg dose is more effective in lowering BPs
from their baseline high values. However, since subjects on 12.5 mg HCTZ combination therapy
reached their BP goals more frequently than the 25 mg dose group, the overall significance of
the superiority of the 25 mg dose is lowered, especially since side effects may have been less
frequent in the 12.5 mg HCTZ group. In view of these findings, patients may find the same
benefit of taking 12.5 mg HCTZ as with 25 mg HCTZ in combination therapy with an ARB.
Therefore, current evidence does not support changing today’s practice of using one particular
dose of HCTZ over the other when used in combination with an ARB for HTN treatment. Long‐
term studies exploring the antihypertensive effects of different doses of HCTZ would be helpful
for determining the therapeutic value of each mmHg reduction in BP, and how each mmHg
reduction in BP effects morbidity and mortality in patients with HTN. If a specific minimum
mmHg reduction in BP is shown to confer maximal long‐term therapeutic benefits, of which
both low and high doses of HCTZ can achieve, then selecting a lower dose of HCTZ in
combination antihypertensive therapy can be justified.
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